Playboy, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
PLBY$1.22-5.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(in thousands, except share and per share amounts)
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Net revenues | $31,714 | $28,994 | $93,168 | $86,017 |
| Costs and expenses: | ||||
| Cost of sales | (7,411) | (6,954) | (25,351) | (25,746) |
| Selling and administrative expenses | (21,164) | (20,434) | (64,154) | (68,197) |
| Impairments | — | (245) | — | (2,087) |
| Other operating income (expense), net | 864 | 5 | 1,674 | (764) |
| Total operating expenses | (27,711) | (27,628) | (87,831) | (96,794) |
| Operating income (loss) | 4,003 | 1,366 | 5,337 | (10,777) |
| Nonoperating (expense) income: | ||||
| Interest expense, net | (2,565) | (1,926) | (7,282) | (5,721) |
| Other income, net | 628 | 460 | 2,155 | 1,662 |
| Total nonoperating expense | (1,937) | (1,466) | (5,127) | (4,059) |
| Income (loss) before income taxes | 2,066 | (100) | 210 | (14,836) |
| (Expense) benefit from income taxes | (202) | 560 | (2,111) | (1,424) |
| Net income (loss) | 1,864 | 460 | (1,901) | (16,260) |
| Net income (loss) per share, basic and diluted | $0.02 | $— | $(0.02) | $(0.17) |
| Weighted-average shares outstanding, basic | 105,243,744 | 102,503,857 | 111,459,543 | 96,558,050 |
| Weighted-average shares outstanding, diluted | 106,109,353 | 112,540,226 | 111,459,543 | 96,558,050 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.